WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Has files: NoSubject: search.filters.subject.Outcome

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib
    (ALPHAMED PRESS, 2016-01-01) Keizman, Daniel; Sarid, David; Lee, Jae L.; Sella, Avishay; Gottfried, Maya; Hammers, Hans; Eisenberger, Mario A.; Carducci, Michael A.; Sinibaldi, Victoria; Neiman, Victoria; Rosenbaum, Eli; Peer, Avivit; Neumann, Avivit; Mermershtain, Wilmosh; Rouvinov, Keren; Berger, Raanan; Yildiz, Ibrahim; Grp, Turkish Oncology
    Background. Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC. Methods. Records from mchRCC patients treated with first-line sunitinib in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC patients were individually matched to mccRCC patients. We compared the clinical benefit rate, progression-free survival (PFS), and overall survival (OS) between the groups. Results. Between 2004 and 2014, 36 patients (median age, 64 years